Bristol-Myers Squibb Continues to Lead the Advancement of Immuno-Oncology with Broad Set of New Data at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

[Business Wire] – Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer and metastatic renal cell carcinoma will be presented at the 50th An more

View todays social media effects on BMY

View the latest stocks trending across Twitter. Click to view dashboard

See who Bristol is hiring next, click here to view